Cue Biopharma announced a reboot Thursday afternoon, bringing in notable biotech executive Shao-Lee Lin as well as a new allergy asset developed in Taiwan and

Q1 earnings recap with Endpoints News After a deal-heavy first quarter, earnings season is in full swing. We’re breaking down the news and trends from

🟢 FDA approves Axsome Therapeutics’ Auvelity for Alzheimer’s agitation: Axsome said up to 76% of patients with Alzheimer’s disease have agitation, which is characterized by

Summit Therapeutics’ stock price $SMMT tumbled nearly 20% after the closing bell Thursday afternoon, following an apparent statistical miss in part of a Phase 3

Amgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA. The company filed a supplement on Wednesday that would